Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

Truist Securities analyst Gregory Renza has maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised the price target from $281 to $286. This adjustment reflects positive sentiment towards the company's performance and market position.